Organization
Immunovant Sciences
8 clinical trials
1 abstract
Clinical trial
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis PatientsStatus: Completed, Estimated PCD: 2020-10-07
Clinical trial
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
IMVT-1401-2501: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants With Graves' Disease (GD)Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' OphthalmopathyStatus: Terminated, Estimated PCD: 2021-02-02
Abstract
ASSOCIATION BETWEEN LIFE EVENTS AND RHEUMATOID ARTHRITIS, RESULTS FROM THE EIRA CASE CONTROL STUDY Org: Immunovant Sciences, Department of public health sciences, KAROLINSKA INSTIUTET, Karolinska University Hospital Stockholm, Clinical epidemiology, Department of Medicine, Rheumatology Unit, Department of Medicine, KAROLINSKA INSTIUTET, Stockholm, Sweden,